Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial

Human immunodeficiency virus (HIV)-1-specific broadly neutralizing monoclonal antibodies are currently under development to treat and prevent HIV-1 infection. We performed a single-center, randomized, double-blind, dose-escalation, placebo-controlled trial of a single administration of the HIV-1 V3-...

Descripción completa

Detalles Bibliográficos
Autores principales: Stephenson, Kathryn E., Julg, Boris, Tan, C. Sabrina, Zash, Rebecca, Walsh, Stephen R., Rolle, Charlotte-Paige, Monczor, Ana N., Lupo, Sofia, Gelderblom, Huub C., Ansel, Jessica L., Kanjilal, Diane G., Maxfield, Lori F., Nkolola, Joseph, Borducchi, Erica N., Abbink, Peter, Liu, Jinyan, Peter, Lauren, Chandrashekar, Abishek, Nityanandam, Ramya, Lin, Zijin, Setaro, Alessandra, Sapiente, Joseph, Chen, Zhilin, Sunner, Lisa, Cassidy, Tyler, Bennett, Chelsey, Sato, Alicia, Mayer, Bryan, Perelson, Alan S., deCamp, Allan, Priddy, Frances H., Wagh, Kshitij, Giorgi, Elena E., Yates, Nicole L., Arduino, Roberto C., DeJesus, Edwin, Tomaras, Georgia D., Seaman, Michael S., Korber, Bette, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516645/
https://www.ncbi.nlm.nih.gov/pubmed/34621054
http://dx.doi.org/10.1038/s41591-021-01509-0

Ejemplares similares

Ejemplares similares